Tasidotin

Drug Profile

Tasidotin

Alternative Names: BSF 223651; ILX 651; LU 223651; SYN-D; Synthadotin; Tasidotin HCl; Tasidotin hydrochloride

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Bioresearch Corporation
  • Developer Genzyme Oncology; Sanofi Oncology
  • Class Antineoplastics; Oligopeptides; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Malignant melanoma; Solid tumours
  • Discontinued Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Malignant-melanoma in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
  • 28 Apr 2011 Phase-I clinical trials in Malignant melanoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top